Jazz Pharmaceuticals plc
Jazz Pharmaceuticals to Terminate Existing Lease and Sign New One
Summary
Jazz Pharmaceuticals, Inc., a subsidiary of Jazz Pharmaceuticals plc, has agreed to terminate its existing commercial lease for a building at 3170 Porter Drive, Palo Alto, California, effective June 30, 2025, upon the landlord securing a tenant to relet the building. Jazz Pharmaceuticals has also entered into a new lease agreement for premises at 3000 El Camino Real, Palo Alto, California, with occupancy expected by July 1, 2025.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement